N-terminal Pro-brain Natriuretic Peptide, High-sensitivity Troponin and Pulmonary Artery Clot Score as Predictors of Right Ventricular Dysfunction in Echocardiography

Granér, Marit; Harjola, Veli‐Pekka; Selander, Tuomas; Laiho, Mia; Piilonen, Anneli; Raade, Merja; Mustonen, Pirjo

doi:10.1016/j.hlc.2015.12.004

Cited by 9 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another interesting study, Granér and colleagues studied 63 normotensive acute PE patients with (n ¼ 32) or without (n ¼ 31) echocardiographic signs of right ventricular dysfunction. 46 The concentration of hs-cTnT was found to be over twofold higher in patients with right ventricular dysfunction than in those without (18.6 vs. 8.1 ng/L; p ¼ 0.014), and was also significantly correlated with the right/left ventricle ratio (p ¼ 0.035) and right ventricle end-diastolic diameter (p ¼ 0.023).…”

Section: Review Of Clinical Evidence Of the Role Of Hs-ctn In Pulmonamentioning

confidence: 92%

Measurement of High-Sensitivity Cardiac Troponin in Pulmonary Embolism: Useful Test or a Clinical Distraction

Lippi

Favaloro

Kavsak

2019

Semin Thromb Hemost

View full text Add to dashboard Cite

The ability to predict death or other unfavorable outcomes after an acute pulmonary embolism (PE) is challenging, with current available risk score models having relatively unsatisfactory prognostic performance in this area. For example, the simplified pulmonary embolism severity index (sPESI), the most frequently used stratification tool, misclassifies a significant percentage of low- and high-risk patients. This gap in care, along with the increasing clinical availability of high-sensitivity cardiac troponin (hs-cTn) laboratory tests and the recent emphasis on detecting myocardial injury, may foster further evaluation of hs-cTn testing in patients with acute PE. Our analysis of the current scientific literature on hs-cTn in patients with acute PE identified that hs-cTn testing may provide valuable information for predicting future adverse outcomes and mortality, independently from baseline clinical risk assessment. Although the risk of an adverse event is indeed higher in patients with higher sPESI scores, cTns retain their prognostic value also in those at low risk, suggesting that a combination of hs-cTn with sPESI may provide an incremental value over assessment of either variable alone. Accordingly, the future development of updated risk stratification models, with the inclusion of laboratory tests such as hs-cTn, may represent an enhanced approach for risk stratification in patients with acute PE. Additional research, however, is needed to verify whether the combination of cTns, specifically as measured with hs-cTn assays, with other biomarkers may further improve the current capacity to efficiently manage patients with acute PE.

show abstract

Section: Review Of Clinical Evidence Of the Role Of Hs-ctn In Pulmonamentioning

confidence: 92%

Measurement of High-Sensitivity Cardiac Troponin in Pulmonary Embolism: Useful Test or a Clinical Distraction

Lippi

Favaloro

Kavsak

2019

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

Choice of marker for assessment of RV dysfunction in acute pulmonary embolism

Ateş

Kundi

et al. 2016

Herz

View full text Add to dashboard Cite

show abstract

Redefining biomarkers in heart failure

et al. 2018

View full text Add to dashboard Cite

Heart failure (HF) is the end result of many different cardiac and non-cardiac abnormalities leading to a complex clinical entity. In this view, the use of biomarkers in HF should be deeply reconsidered; indeed, the same biomarker may carry a different significance in patients with preserved or reduced EF. The aim of this review is to reconsider the role of biomarkers in HF, based on the different clinical characteristics of this syndrome. The role of cardiac and non-cardiac biomarkers will be reviewed with respect of the different clinical manifestations of this syndrome.

show abstract

N-terminal Pro-brain Natriuretic Peptide, High-sensitivity Troponin and Pulmonary Artery Clot Score as Predictors of Right Ventricular Dysfunction in Echocardiography

Abstract: Normal age- and sex dependent NT-proBNP on admission or measured five days later seems to be useful in exclusion of RVD at follow up. Total PA clot score shows only to be of modest benefit for predicting persistent RVD.

Cited by 9 publications

References 33 publications

Measurement of High-Sensitivity Cardiac Troponin in Pulmonary Embolism: Useful Test or a Clinical Distraction

Measurement of High-Sensitivity Cardiac Troponin in Pulmonary Embolism: Useful Test or a Clinical Distraction

Choice of marker for assessment of RV dysfunction in acute pulmonary embolism

Redefining biomarkers in heart failure

Contact Info

Product

Resources

About